NCT06586580Completed
Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1
Le Traitement Par Lenvatinib + Anti-PD1 Du Mélanome Métastatique
Source: ClinicalTrials.gov · Last updated 19 Sept 2024
Brief summary (registry, in English)
The hypothesis is that treatment with Lenvatinib + Pembrolizumab is less effective in real life than in clinical trials. In fact, an objective response rate \< 20% and a worse tolerability of the treatment in real life with ≥50% of severe toxicities are expected.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 18 (actual)
- First submitted
- 4 Sept 2024
- Start date
- 30 Mar 2023
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Centre Hospitalier Universitaire de Besancon
- Diseases
- Melanoma
- NCT number
- NCT06586580
What you commit to
- Study type: Observational
- Participants enrolled: 18
- From 30 Mar 2023 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Uveal melanoma
Who the study is looking for
- Metastatic melanoma (stage III non operable or stage IV according to American Joint Committee on Cancer staging rules) refractory to immunotherapy (≥ 2nd treatment line after minimum a failure of immunotherapy)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Besançon Coordinator of this site? Confirm its status | Besançon | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.